Focus Partners Wealth Raises Stock Position in Danaher Corporation $DHR

Focus Partners Wealth lifted its position in Danaher Corporation (NYSE:DHR) by 130.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 663,346 shares of the conglomerate’s stock after acquiring an additional 375,234 shares during the quarter. Focus Partners Wealth owned 0.09% of Danaher worth $151,871,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new stake in shares of Danaher in the 3rd quarter worth about $25,000. Elevated Capital Advisors LLC bought a new stake in shares of Danaher in the 4th quarter worth about $26,000. WFA of San Diego LLC bought a new stake in shares of Danaher in the 2nd quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Danaher in the 3rd quarter worth about $27,000. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Danaher in the 4th quarter worth about $27,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.5%

Shares of DHR opened at $179.95 on Friday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a 50-day moving average of $180.93 and a 200 day moving average of $204.78. The firm has a market capitalization of $127.37 billion, a price-to-earnings ratio of 34.81, a PEG ratio of 2.40 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business posted $1.88 EPS. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, research analysts expect that Danaher Corporation will post 8.45 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s payout ratio is currently 30.95%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DHR. TD Cowen lowered their target price on shares of Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Citigroup began coverage on shares of Danaher in a report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price for the company. Argus lowered their target price on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Friday, April 24th. Rothschild & Co Redburn set a $205.00 target price on shares of Danaher in a report on Friday, April 17th. Finally, UBS Group decreased their price objective on shares of Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $233.61.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.